MAXIMEC INJECTION FOR PIGS 1% W/V SOLUTION FOR INJECTION
Land: Irland
Språk: engelsk
Kilde: HPRA (Health Products Regulatory Authority)
Preparatomtale
(SPC)
15-12-2015
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
IVERMECTIN
Tilgjengelig fra:
Cross Vetpharm Group Limited
ATC-kode:
QP54AA01
INN (International Name):
IVERMECTIN
Dosering :
1.0 %w/v
Legemiddelform:
Solution for Injection
Resept typen:
LM-Licensed Merchant
Terapeutisk gruppe:
Porcine
Terapeutisk område:
Ivermectin
Indikasjoner:
Endectoparasiticides
Autorisasjon status:
Authorised
Autorisasjon dato:
2004-10-19
Preparatomtale
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Maximec Injection for Pigs 1% w/v Solution for Injection.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substance
Ivermectin
1.0%w/v
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
A clear, colourless, slightly viscous, non-aqueous sterile solution
.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Pigs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In swine: treatment of the infections by the following parasites:
GASTROINTESTINAL ROUNDWORMS: (Adults and fourth stage larvae):
_Ascaris suum_
_Hyostrongylus rubidus_
_Oesophagostomum spp._
_Strongyloides ransomi _(adult)
LUNGWORMS:
_Metastrongylus spp_. (adult)
LICE:
_Haematopinus suis_
MANGE MITES:
_Sarcoptes scabiei _var. _suis_
4.3 CONTRAINDICATIONS
Do not use in case of known hypersensitivity to the active substance.
Do not administer by the intravenous or intramuscular route.
Do not use in cats or dogs as severe adverse reactions may occur.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 30/11/2015_
_CRN 7022356_
_page number: 1_
Details provided above apply. See also points 4.3, 4.5 and 4.7.
Care should be taken to avoid the following practices because they increase the risk of development of resistance and
could ultimately result in ineffective therapy:
-
Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
-
Underdosing, which may be due to underestimation of body weight, misadministration of the product, or
lack of calibration of the dosing device.
Suspected clinical cases of resistance to anthelmintics should be further inv
Les hele dokumentet
